Venturi Wealth Management LLC Invests $143,000 in Roivant Sciences Ltd. (NASDAQ:ROIV)

Venturi Wealth Management LLC acquired a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,067 shares of the company’s stock, valued at approximately $143,000.

Several other large investors also recently added to or reduced their stakes in the business. TOMS Capital Investment Management LP purchased a new stake in Roivant Sciences during the third quarter valued at about $46,333,000. FMR LLC increased its holdings in shares of Roivant Sciences by 5.6% in the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock worth $567,134,000 after buying an additional 2,593,910 shares during the period. Geode Capital Management LLC increased its holdings in shares of Roivant Sciences by 23.2% in the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock worth $89,400,000 after buying an additional 1,460,205 shares during the period. State Street Corp increased its holdings in shares of Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company’s stock worth $225,737,000 after buying an additional 1,118,561 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Roivant Sciences by 49.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,307,178 shares of the company’s stock worth $26,625,000 after buying an additional 762,953 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $10.68 on Friday. The stock has a market capitalization of $7.62 billion, a PE ratio of -71.20 and a beta of 1.25. Roivant Sciences Ltd. has a 1 year low of $9.76 and a 1 year high of $13.06. The business’s 50-day moving average is $11.21 and its 200 day moving average is $11.59.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, equities research analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Roivant Sciences

In other news, CAO Rakhi Kumar sold 227,500 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the sale, the chief accounting officer now directly owns 163,264 shares of the company’s stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was bought at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 2,288,170 shares of company stock valued at $26,547,299. 7.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on ROIV. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Roivant Sciences has a consensus rating of “Buy” and an average target price of $18.08.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.